A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Our mission is to develop transformative, interventional technologies that allow eyecare providers to procedurally elevate the standards of care – empowering people to keep seeing. We are passionate about improving patients’ lives by helping them to preserve their sight. Our business philosophy is grounded in the following principles: comprehensively understanding disease physiology; developing transformative technologies that are intended to preserve, protect, and restore natural physiological functionality to diseased eyes; developing and marketing products with proven clinical evidence that achieve superior effectiveness versus current treatment paradigms while minimizing complications or side effects; providing intuitive, patient-friendly, interventional solutions to eye care professionals ("ECPs"); and delivering compelling economic value to all stakeholders, including patients, providers and third-party payors such as Medicare and commercial insurers.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 77M | 77M | 80M | 81M | 71M | 49M |
| Net Income | -38M | -38M | -52M | -56M | -86M | -63M |
| EPS | $-0.74 | $-0.74 | $-1.03 | $-1.14 | $-1.80 | $-2.36 |
| Free Cash Flow | -30M | -30M | -23M | -48M | -77M | -53M |
| ROIC | -238.7% | -36.9% | -40.6% | -36.6% | -44.6% | -23.8% |
| Gross Margin | 86.2% | 86.2% | 85.5% | 85.3% | 82.7% | 82.4% |
| Debt/Equity | 0.63 | 0.63 | 0.45 | 0.30 | 0.21 | 0.14 |
| Dividends/Share | $0.00 | $0.00 | - | - | - | - |
| Operating Income | -37M | -37M | -51M | -57M | -84M | -51M |
| Operating Margin | -48.0% | -48.0% | -63.3% | -70.7% | -117.7% | -105.2% |
| ROE | -60.1% | -50.7% | -58.8% | -46.2% | -53.9% | -27.1% |
| Shares Outstanding | 52M | 52M | 50M | 49M | 48M | 27M |
| Metric | 2020 | 2021 | 2022 | 2023 | |||
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 28M | 49M | 71M | 81M | 80M | 77M | 77M |
| Gross Margin | 66.7% | 82.4% | 82.7% | 85.3% | 85.5% | 86.2% | 86.2% |
| R&D | 8.9M | 16M | 23M | 18M | 18M | 15M | 15M |
| SG&A | 42M | 76M | 120M | 109M | 101M | 89M | 89M |
| EBIT | -32M | -51M | -84M | -57M | -51M | -37M | -37M |
| Op. Margin | -116.5% | -105.2% | -117.7% | -70.7% | -63.3% | -48.0% | -48.0% |
| Net Income | -35M | -63M | -86M | -56M | -52M | -38M | -38M |
| Net Margin | -125.5% | -128.6% | -120.9% | -68.5% | -64.5% | -49.7% | -49.7% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||
| ROIC | -44.2% | -23.8% | -44.6% | -36.6% | -40.6% | -36.9% | N/M |
| ROE | N/A | -27.1% | -53.9% | -46.2% | -58.8% | -50.7% | -60.1% |
| ROA | -47.7% | -22.5% | -40.5% | -33.3% | -36.1% | -29.8% | -33.3% |
| Cash Flow | |||||||
| Op. Cash Flow | -32M | -53M | -76M | -47M | -22M | -30M | -30M |
| Free Cash Flow | -33M | -53M | -77M | -48M | -23M | -30M | -30M |
| Owner Earnings | -33M | -58M | -90M | -62M | -40M | -43M | -43M |
| CapEx | 953K | 813K | 970K | 791K | 385K | 224K | 224K |
| Maint. CapEx | 554K | 632K | 710K | 614K | 712K | 487K | 487K |
| Growth CapEx | 399K | 181K | 260K | 177K | 0 | 0 | 0 |
| D&A | 554K | 632K | 710K | 614K | 712K | 487K | 487K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | 0.0% | 0.0% |
| Stock-Based Comp | 497K | 5.1M | 13M | 15M | 17M | 13M | 13M |
| Debt Repayment | 142K | 0 | 0 | 0 | 238K | 0 | 0 |
| Balance Sheet | |||||||
| Net Debt | -91M | -489M | -337M | -240M | -201M | -144M | -52M |
| Cash & Equiv. | 62M | 261M | 185M | 138M | 120M | 92M | 92M |
| Long-Term Debt | 32M | 33M | 33M | 32M | 39M | 40M | 40M |
| Debt/Equity | -0.36 | 0.14 | 0.21 | 0.30 | 0.45 | 0.63 | 0.63 |
| Interest Coverage | -13.4 | -11.8 | -18.8 | -10.6 | -10.8 | -7.2 | -7.2 |
| Equity | -89M | 232M | 160M | 120M | 88M | 64M | 64M |
| Total Assets | 73M | 280M | 213M | 167M | 143M | 115M | 115M |
| Total Liabilities | 44M | 48M | 53M | 46M | 55M | 51M | 51M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | 0 | 0 |
| Retained Earnings | -90M | -153M | -239M | -295M | -346M | -385M | -385M |
| Working Capital | 61M | 264M | 192M | 151M | 124M | 102M | 102M |
| Current Assets | 71M | 277M | 210M | 163M | 140M | 113M | 113M |
| Current Liabilities | 9.3M | 14M | 18M | 12M | 15M | 11M | 11M |
| Per Share Data | |||||||
| EPS | -3.71 | -2.36 | -1.80 | -1.14 | -1.03 | -0.74 | -0.74 |
| Owner EPS | -0.70 | -2.18 | -1.87 | -1.28 | -0.80 | -0.83 | -0.83 |
| Book Value | -1.87 | 8.70 | 3.34 | 2.47 | 1.75 | 1.23 | 1.23 |
| Cash Flow/Share | -0.68 | -1.97 | -1.59 | -0.97 | -0.45 | -0.57 | -0.73 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | 0.00 | 0.00 |
| Shares Out. | 47.6M | 26.7M | 47.9M | 48.7M | 50.0M | 51.9M | 51.9M |
| Valuation | |||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | -5.2 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 2.0 | 3.5 | 2.2 | 2.0 | N/A | 3.1 |
| Price/Sales | N/A | 14.8 | 7.1 | 4.5 | 3.4 | N/A | 2.6 |
| FCF Yield | N/A | -11.5% | -13.6% | -17.8% | -12.7% | N/A | -15.1% |
| Market Cap | N/A | 464M | 568M | 269M | 179M | 0 | 198M |
| Avg. Price | N/A | 27.24 | 10.62 | 7.48 | 5.50 | 0.00 | 3.82 |
| Year-End Price | N/A | 17.40 | 11.85 | 5.53 | 3.57 | 0.00 | 3.82 |
Sight Sciences, Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 84.4%.
Sight Sciences, Inc. (SGHT) has a 5-year average return on invested capital (ROIC) of -36.5%. This is below average and may indicate limited pricing power.
Sight Sciences, Inc. (SGHT) has a market capitalization of $198M. It is classified as a small-cap stock.
Sight Sciences, Inc. (SGHT) does not currently pay a regular dividend.
Sight Sciences, Inc. (SGHT) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
Sight Sciences, Inc. (SGHT) reported annual revenue of $77 million in its most recent fiscal year, based on SEC EDGAR filings.
Sight Sciences, Inc. (SGHT) has a net profit margin of -49.7%. The company is currently unprofitable.
Sight Sciences, Inc. (SGHT) generated $-30 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Sight Sciences, Inc. (SGHT) has a debt-to-equity ratio of 0.63. This indicates moderate leverage.
Sight Sciences, Inc. (SGHT) reported earnings per share (EPS) of $-0.74 in its most recent fiscal year.
Sight Sciences, Inc. (SGHT) has a return on equity (ROE) of -50.7%. A negative ROE may indicate losses or negative equity.
Sight Sciences, Inc. (SGHT) has a 5-year average gross margin of 84.4%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 6 years of financial data for Sight Sciences, Inc. (SGHT), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Sight Sciences, Inc. (SGHT) has a book value per share of $1.23, based on its most recent annual SEC filing.